1. Ruxolitinib may effectively treat parkinsonism arising from treatment with ciltacabtagene autoleucel in patients with multiple myeloma.
2. Two cases were detailed in a recent report, both of which showed successful control of parkinsonism with ruxolitinib.
3. Parkinsonism arising from ciltacabtagene autoleucel therapy has a distinct pathogenesis from Parkinson’s disease.
4. CAR T-cell therapy for multiple myeloma necessitates optimized therapy for potentially life-threatening complications, including parkinsonism.
